433220-01-0

Upstream product

• 433219-88-6 (1-cyclohexylmethyl-cyclobutyl)-methanol 
• 5469-33-0 cyclohexylmethyl iodide 
• 3721-95-7 Cyclobutanecarboxylic acid 
• 69739-34-0 t-butyldimethylsiyl triflate 

Downstream Products

• 433220-14-5 (E)-1-iodo-4-(tert-butyldimethylsiloxy)-6-cyclohexyl-5,5-trimethylene-1-hexene 
• 212310-12-8 (Z)-7-{(1R,2R,3R)-2-[(E)-(R)-4-(1-Cyclohexylmethyl-cyclobutyl)-4-hydroxy-but-1-enyl]-3-hydroxy-5-oxo-cyclopentyl}-hept-5-enoic acid methyl ester 
• 433220-29-2 (Z)-7-{(1R,2R,3R)-3-(tert-Butyl-dimethyl-silanyloxy)-2-[(E)-4-(tert-butyl-dimethyl-silanyloxy)-4-(1-cyclohexylmethyl-cyclobutyl)-but-1-enyl]-5-oxo-cyclopentyl}-hept-5-enoic acid methyl ester 

Relevant academic research and scientific papers

Development of a highly selective EP2-receptor agonist. Part 1: Identification of 16-hydroxy-17,17-trimethylene PGE2 derivatives

Design and synthesis of an EP2-receptor selective agonist began with the chemical modification of α and ω-chains of butaprost 1a, which exhibits an affinity for the IP-receptor. Two series of prostaglandin (PG) analogues with a 16-hydroxy-17,17-trimethylene moiety as an ω-chain were identified. Among those tested, 4a,b,e,f,h and 6a,b,e,f,h were found to be highly selective EP2-receptor agonists. Structure activity relationships are discussed. Copyright